Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dynamic Biotechnology & Genome Invesco ETF (PBE)

Dynamic Biotechnology & Genome Invesco ETF (PBE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Profit from the Genomics Market Momentum With These ETFs

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

GSK : 40.89 (-0.34%)
PBE : 58.54 (+0.53%)
ARKG : 49.56 (+2.86%)
GNOM : 16.89 (+1.38%)
IDNA : 37.01 (+1.59%)
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

AZN : 55.22 (-0.11%)
PFE : 37.50 (+0.64%)
MRK : 76.37 (-0.24%)
LLY : 151.16 (-0.74%)
MYGN : 14.73 (+0.27%)
IMMU : 34.47 (-0.69%)
IBB : 133.34 (+0.66%)
CNCR : 27.45 (+0.99%)
XBI : 106.05 (+1.20%)
PBE : 58.54 (+0.53%)
Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir

As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.

GILD : 73.34 (-0.22%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
BBH : 158.22 (+0.75%)
PBE : 58.54 (+0.53%)
First-Mover Pandemic Disease Fight ETF On The Way

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

REGN : 569.91 (+1.59%)
GILD : 73.34 (-0.22%)
IMMU : 34.47 (-0.69%)
SBIO : 42.66 (+0.33%)
PBE : 58.54 (+0.53%)
MYOK : 107.50 (+0.72%)
IOVA : 41.00 (+7.47%)
ARKG : 49.56 (+2.86%)
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

GILD : 73.34 (-0.22%)
IBB : 133.34 (+0.66%)
CNCR : 27.45 (+0.99%)
BBH : 158.22 (+0.75%)
FBT : 164.94 (+0.42%)
PTH : 115.89 (-0.14%)
IHF : 193.85 (-0.08%)
IHE : 153.64 (-0.20%)
XPH : 43.17 (-0.02%)
SBIO : 42.66 (+0.33%)
XHS : 67.52 (-0.28%)
PBE : 58.54 (+0.53%)
IDNA : 37.01 (+1.59%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
JNJ : 144.37 (-1.59%)
LLY : 151.16 (-0.74%)
BMY : 60.79 (-0.57%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
JNJ : 144.37 (-1.59%)
BMY : 60.79 (-0.57%)
LLY : 151.16 (-0.74%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
BMY : 60.79 (-0.57%)
JNJ : 144.37 (-1.59%)
LLY : 151.16 (-0.74%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

CNCR : 27.45 (+0.99%)
BBC : 42.93 (+1.20%)
PBE : 58.54 (+0.53%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
SBIO : 42.66 (+0.33%)
IDNA : 37.01 (+1.59%)
HTEC : 29.45 (+0.83%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
BIIB : 304.53 (+0.02%)
VRTX : 284.96 (+0.12%)
NBIX : 124.80 (+3.00%)
A Guide to Biotech ETF Investing

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

SBIO : 42.66 (+0.33%)
BBP : 46.70 (+0.47%)
BTEC : 43.46 (+0.98%)
BBH : 158.22 (+0.75%)
XBI : 106.05 (+1.20%)
IBB : 133.34 (+0.66%)
FBT : 164.94 (+0.42%)
CNCR : 27.45 (+0.99%)
PBE : 58.54 (+0.53%)
ARKG : 49.56 (+2.86%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
VRTX : 284.96 (+0.12%)
BIIB : 304.53 (+0.02%)
NBIX : 124.80 (+3.00%)
Genomics ETFs Surge on CRISPR's Gene Editing Progress

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

PBE : 58.54 (+0.53%)
VRTX : 284.96 (+0.12%)
CRSP : 69.94 (+3.19%)
ARKG : 49.56 (+2.86%)
IDNA : 37.01 (+1.59%)
GNOM : 16.89 (+1.38%)
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

PTH : 115.89 (-0.14%)
PBE : 58.54 (+0.53%)
XBI : 106.05 (+1.20%)
CNCR : 27.45 (+0.99%)
DXCM : 405.25 (+1.47%)
CLVS : 7.01 (-6.91%)
BIIB : 304.53 (+0.02%)
PTI : 1.6300 (-2.40%)
AQST : 5.75 (-6.50%)
FTSV : 95.51 (+0.05%)
ARKG : 49.56 (+2.86%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
CELG : 108.24 (+0.10%)
VRTX : 284.96 (+0.12%)
BIIB : 304.53 (+0.02%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
CELG : 108.24 (+0.10%)
GILD : 73.34 (-0.22%)
BIIB : 304.53 (+0.02%)
ETFs Poised to Benefit from Gene Editing Revolution

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

AGN : 193.02 (+0.02%)
PBE : 58.54 (+0.53%)
ONCE : 110.05 (-3.10%)
EDIT : 30.10 (+2.80%)
ARKG : 49.56 (+2.86%)
GNOM : 16.89 (+1.38%)
IDNA : 37.01 (+1.59%)
ETFs to Gain From the Booming Genomics Market

Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.

PBE : 58.54 (+0.53%)
ILMN : 354.70 (+1.51%)
IDNA : 37.01 (+1.59%)
GNOM : 16.89 (+1.38%)
ARKG : 49.56 (+2.86%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 58.54 (+0.53%)
IBB : 133.34 (+0.66%)
XBI : 106.05 (+1.20%)
INCY : 99.37 (+0.70%)
VRTX : 284.96 (+0.12%)
AMGN : 226.43 (+0.73%)
Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

NVS : 84.91 (-0.09%)
BMY : 60.79 (-0.57%)
BBH : 158.22 (+0.75%)
PJP : 63.68 (+0.20%)
IBB : 133.34 (+0.66%)
PBE : 58.54 (+0.53%)
CELG : 108.24 (+0.10%)
AMGN : 226.43 (+0.73%)
IEIH : 29.36 (+0.06%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.19 , SEDG -6.12 , THC -0.17 , TER +1.01 , LITE +1.84
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar